189 related articles for article (PubMed ID: 35394238)
1. PET-CT imaging of pulmonary inflammation using [
Puuvuori E; Liggieri F; Velikyan I; Chiodaroli E; Sigfridsson J; Romelin H; Ingvast S; Korsgren O; Hulsart-Billström G; Perchiazzi G; Eriksson O
EJNMMI Res; 2022 Apr; 12(1):19. PubMed ID: 35394238
[TBL] [Abstract][Full Text] [Related]
2. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
3. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
5. Physiological Biodistribution of
Özgüven S; Filizoğlu N; Kesim S; Öksüzoğlu K; Şen F; Öneş T; İnanır S; Turoğlu HT; Erdil TY
Mol Imaging Radionucl Ther; 2021 Feb; 30(1):39-46. PubMed ID: 33586406
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
8. Imaging of atherosclerosis with [
Grandjean CE; Pedersen SF; Christensen C; Dibenedetto A; Eriksen T; Binderup T; Kjaer A
Sci Rep; 2023 Jun; 13(1):9249. PubMed ID: 37286582
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of
Ma G; Du J; Zhang X; Liu J; Xu X; Xu B; Guan Z
Quant Imaging Med Surg; 2022 Apr; 12(4):2427-2440. PubMed ID: 35371938
[TBL] [Abstract][Full Text] [Related]
10. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors.
Novruzov F; Aliyev A; Wan MYS; Syed R; Mehdi E; Aliyeva I; Giammarile F; Bomanji JB; Kayani I
Eur J Hybrid Imaging; 2021 May; 5(1):10. PubMed ID: 34181114
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
Ocak M; Demirci E; Kabasakal L; Aygun A; Tutar RO; Araman A; Kanmaz B
Nucl Med Commun; 2013 Nov; 34(11):1084-9. PubMed ID: 23939265
[TBL] [Abstract][Full Text] [Related]
12. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
13. Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway.
Klingenstein A; Haug AR; Miller C; Hintschich C
Orbit; 2015 Feb; 34(1):16-22. PubMed ID: 25264824
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
15. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
[TBL] [Abstract][Full Text] [Related]
16. Al[
Haeger A; Soza-Ried C; Kramer V; Hurtado de Mendoza A; Eppard E; Emmanuel N; Wettlin J; Amaral H; Fernández R
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672388
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, pharmacokinetics, dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617
[TBL] [Abstract][Full Text] [Related]
18. Highly variable biodistribution of
Cheng M; Tann M
Hepatobiliary Surg Nutr; 2022 Oct; 11(5):654-661. PubMed ID: 36268247
[TBL] [Abstract][Full Text] [Related]
19. Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT.
Kunikowska J; Królicki L; Pawlak D; Zerizer I; Mikołajczak R
Clin Nucl Med; 2012 Nov; 37(11):1052-7. PubMed ID: 22996234
[TBL] [Abstract][Full Text] [Related]
20. Correlations between [
Bruvoll R; Blakkisrud J; Mikalsen LT; Connelly J; Stokke C
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
